Optical biosensors have led to significant advancements in virus detection and imaging capabilities. Coupled with advanced instrumentation, they have enabled higher sensitivities while increasing the rate at which samples can be tested. These techniques can be developed into point-of-care (POC) diagnostics for viral detection and are promising alternatives to detect COVID-19.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiology of coronavirus disease 2019 (COVID-19), is readily transmitted person to person. Optimal control of COVID-19 depends on directing resources and health messaging to mitigation efforts that are most likely to prevent transmission, but the relative importance of such measures has been disputed.
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has caused a global pandemics. To facilitate the detection of SARS-CoV-2 infection, various RT-LAMP assays using 19 sets of primers had been developed, but never been compared.
Lateral flow devices for asymptomatic mass testing are proving controversial. At the heart of the matter is a flawed process, with the decision to implement society-wide “Moonshot” testing made before robust field evaluations of the tests were completed. Subsequent selective emphasis of unrealistic performance estimates has caused confusion. Little surprise we are now in a mess.
Acute coronavirus disease 2019 (COVID-19) is primarily diagnosed via reverse transcription-polymerase chain reaction (RT-PCR) detection of viral genetic material. However, considering the three primary modes of transmission of SARS-Cov-2 i.e., contact, droplet and aerosol routes, various types of samples have been suggested for the purpose of detection.